Evidence map›Paper›PMID 31348746›Full record

ArticleCanadian Urological Association journal = Journal de l'Association des urologues du Canada2020

Outcomes and prognosticators of stage 4 renal cell carcinoma with pathological T4 primary lesion using a large, Canadian, multi-institutional database.

Justin D Oake, Premal Patel, Luke T Lavallée, Jean-Baptiste Lattouf, Olli Saarela, Laurence Klotz, Ronald B Moore, Anil Kapoor, Antonio Finelli, Ricardo A Rendon and 3 more

Open access · diamondAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Canadian Urological Association journal = Journal de l'Association des urologues du Canada, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
1.0field-weighted citation impact, top 21% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 7 citations in OpenAlex.

  1. Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors at 10 institutions in 2 countries.

Justin D OakeSection of Urology, University of Manitoba, Winnipeg, MB, Canada.
Premal PatelDepartment of Urology, University of Miami, Miami, FL, United States.
Luke T LavalléeDivision of Urology, University of Ottawa, ON, Canada.
Jean-Baptiste LattoufSection of Urology, University of Montreal, Montreal, QC, Canada.
Olli SaarelaDalla Lana School of Public Health, University of Toronto, Toronto, ON, Canada.
Laurence KlotzDivision of Urology, University of Toronto, Toronto, ON, Canada.
Ronald B MooreDivision of Urology, University of Alberta, Edmonton, AB, Canada.
Anil KapoorDivision of Urology, McMaster University, Hamilton, ON, Canada.
Antonio FinelliDivision of Urology, University of Toronto, Toronto, ON, Canada.
Ricardo A RendonDepartment of Urology, Dalhousie University, Halifax, NS, Canada.
Jun KawakamiDivision of Urology, University of Calgary, Calgary, AB, Canada.
Alan I SoDepartment of Urologic Sciences, University of British Columbia, Vancouver, BC, Canada.
Darrel E DrachenbergSection of Urology, University of Manitoba, Winnipeg, MB, Canada.
University of Toronto · CAUniversity of Manitoba · CADalhousie University · CAMcMaster University · CAUniversité de Montréal · CAUniversity of Alberta · CAUniversity of British Columbia · CAUniversity of Calgary · CAUniversity of Miami · USUniversity of Ottawa · CA

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

introductionThe primary objective of this study was to evaluate outcomes and prognosticators in patients who underwent radical nephrectomy (RN) or cytoreductive nephrectomy (CN), depending on the clinical stage of disease preoperatively, with a pathological T4 (pT4) renal cell carcinoma (RCC) outcome. There is little data on the outcome of this specific subset of patients.

methodsFrom 2009-2016, we identified patients in the Canadian Kidney Cancer information system (CKCis) who underwent RN or CN and were found to have pT4 RCC. Clinical, operative, and pathological variables were analyzed with univariable and multivariable Cox proportional hazard models to identify factors associated with overall survival (OS). Survival curves were created using Kaplan-Meier methods and compared using the log-rank test.

resultsA total of 82 patients were included in the study cohort. Median patient age was 62 years (interquartile range [IQR] 55, 70). Fifty (61%) patients had clear-cell histology and 14 (17%) had sarcomatoid characteristics. Median followup was 12 months (IQR 3, 24). At last followup, eight (10%) patients are alive with no evidence of disease, 27 (33%) are alive with disease, four (5%) were lost to followup, 36 (44%) died of disease, and seven (8%) died of other causes. Tumor histological subtype (clear-cell vs. non-clear-cell) (p=0.0032), larger tumor size (cm) (p=0.012), and Fuhrman grade (G4 vs. G2-G3) (p=0.045) were significantly associated with mortality in a multivariable Cox regression model.

conclusionsFor patients with pT4 RCC after RN or CN, survival is poor. Sarcomatoid features, non-clear-cell histology, and presence of systemic symptoms were associated with worse OS.

Identifiers

PMID31348746
PMCPMC7012283
OpenAlexW2963960724

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.